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Abstract
Background: Chronic non-cancer pain is a common problem that is often accompanied by psychiatric comorbidity and
disability. The effectiveness of a multi-disciplinary pain management program was tested in a 3 month before and after trial.
Methods: Providers in an academic general medicine clinic referred patients with chronic non-cancer pain for participation in
a program that combined the skills of internists, clinical pharmacists, and a psychiatrist. Patients were either receiving opioids
or being considered for opioid therapy. The intervention consisted of structured clinical assessments, monthly follow-up, pain
contracts, medication titration, and psychiatric consultation. Pain, mood, and function were assessed at baseline and 3 months
using the Brief Pain Inventory (BPI), the Center for Epidemiological Studies-Depression Scale scale (CESD) and the Pain Disability
Index (PDI). Patients were monitored for substance misuse.
Results: Eighty-five patients were enrolled. Mean age was 51 years, 60% were male, 78% were Caucasian, and 93% were
receiving opioids. Baseline average pain was 6.5 on an 11 point scale. The average CESD score was 24.0, and the mean PDI score
was 47.0. Sixty-three patients (73%) completed 3 month follow-up. Fifteen withdrew from the program after identification of
substance misuse. Among those completing 3 month follow-up, the average pain score improved to 5.5 (p = 0.003). The mean
PDI score improved to 39.3 (p < 0.001). Mean CESD score was reduced to 18.0 (p < 0.001), and the proportion of depressed
patients fell from 79% to 54% (p = 0.003). Substance misuse was identified in 27 patients (32%).
Conclusions: A primary care disease management program improved pain, depression, and disability scores over three months
in a cohort of opioid-treated patients with chronic non-cancer pain. Substance misuse and depression were common, and many
patients who had substance misuse identified left the program when they were no longer prescribed opioids. Effective care of
patients with chronic pain should include rigorous assessment and treatment of these comorbid disorders and intensive efforts
to insure follow up.
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Chronic, non-cancer pain, defined as pain of greater than
3 months duration, is a common, important health issue.
The prevalence of chronic pain ranges from 20% to 60%
[1]. The prevalance of low back pain is greater than
30%[2], and the prevalance of migraine is approximately
15%[3,4]. Pain disorders, including headache, back pain,
arthritis and other musculoskeletal pain, are estimated to
cost the United States economy $61 billion per year in lost
productive time [5]. It is frequently asserted that chronic
non-cancer pain is undertreated [6-8].
The optimal approach to treating chronic pain is contro-
versial [9-13]. The realization that acute pain and cancer
pain were often undertreated led to a liberalization of opi-
oid use in these populations in the late 1980's and
throughout the 1990's [6,14-16]. Subsequently, many
advocates and practitioners called for an increase in the
use of opioids for patients with chronic non-cancer pain
as well [14,17,18]. Other experts assert that use of opioids
for chronic pain should be limited [10,19]). used with
caution [20], or eschewed altogether due to potential for
substance misuse and lack of proven efficacy [13].
In large part, uncertainty about how to best manage
patients with chronic pain stems from a lack of research in
this area [21]. The limited available research comes from
studies performed in specialty practice settings [11,22-
25]; few studies have examined the care of chronic pain in
primary care [26,27]. Unlike other common chronic dis-
eases such as congestive heart failure or diabetes, there are
few clinical trials to inform practice guidelines.
Chronic pain management is complex. Like other chronic
diseases, chronic pain is multi-faceted, and it is attended
by its own set of comorbidities. It is complicated by sub-
stantial psychological and functional impairment in the
forms of depression, disability, and loss of livelihood [28-
30]. It is also costly. Patients with depression and back
pain or migraine incur 3 to 4 times higher medical costs
than patients with these pain conditions alone [31].
Generalists, even if well-versed in the biopsychosocial
model of disease, often feel unprepared to manage
chronic pain. They may lack the training in using certain
pharmacological regimens, such as combining chronic
opioids with psychiatric and pain modulating agents
[27,32]. They may fear regulatory scrutiny and sanction
when prescribing opioids, and they may be wary of foster-
ing opioid dependence, misuse or addiction [33,34].
These barriers result in variations and inconsistencies in
care that leave both patients and providers frustrated.
We developed a disease management program to improve
the management of chronic pain in opioid-treated
patients attending an academic general medicine practice.
Traditional models of office-based care focus on diagnon-
sis and acute management of medical problems in the
context of a single provider-patient relationship. In con-
trast, disease management emphasizes: (1.) The use of
multi-disciplinary teams providing integrated care; (2.)
Evidence-based algorithms; (3.) Interval visits to monitor
response to therapy; and (4.) Information systems that
permit tracking of outcomes and adjustment of therapy
[35-39]. We applied these principles in developing and
implementing an intensive, structured, and coordinated
program to improve the management of patient with
chronic pain. We focused our program on patients treated
with opioid medications and attempted to provide an
environment that would allow the safe and effective use of
these drugs. We sought to determine if this program could
improve pain, functional, and psychiatric outcomes in a 3
month uncontrolled trial.
Methods
Development of the program
In designing the program, we reviewed existing research,
contacted experts, and conducted informal assessments of
the main barriers to effective pain management in our
practice [40]. Barriers existed at the provider and patient
levels. These included part-time providers, frequent pro-
vider turnaround, physicians in training, and a socio-eco-
nomically-disadvantaged, geographically dispersed
patient population with multiple comorbidities. We
applied lessons and systems from existing disease state
management programs in diabetes, anticoagulation, and
heart failure in our practice [41].
Patient recruitment
Patients were eligible if they had pain of greater than 3
months duration and were either taking or considering
opioid therapy. Attending and resident physicians were
encouraged to refer patients if they were having difficulty
managing their pain or if they suspected misuse of opioid
medications. We publicized the program through educa-
tional conferences with residents and attendings and
through informal communication within our practice.
Baseline assessment
After obtaining informed consent, a research assistant
administered a comprehensive baseline assessment to
gather socio-demographic data and review the medical
history with an emphasis on the medical management of
pain. Validated measures of pain, disability and psycho-
logical status were included. Using an 11 point scale, the
Brief Pain Inventory (BPI) asked patients to rate their pain
at the time of the interview and at its worst, least, and aver-
age over the past month [42,43]. The 7 item Pain Disabil-
ity Index (PDI), a measure of pain related disability, asked
patients to rate the degree of disability on a 10 point scalePage 2 of 13
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scale discriminates between high and low levels of disabil-
ity. To assess depression, we used the Center for Epidemi-
ological Studies-Depression Scale (CESD) [48]. This
twenty item tool rates affective symptoms on a scale of 0
to 3.
Intervention
Patients were managed by a multi-disciplinary team con-
sisting of the patient's primary care physician, a clinical
pharmacist, a program assistant with training in health
behavior, and a psychiatrist with sub-specialization in
pain management who saw patients with the team one
half-day per week. One nurse was dedicated to checking-
in study patients and obtaining urine specimens. At entry,
all patients signed a Medication Contract (Appendix A)
[49] and provided a sample of urine for toxicological test-
ing (UTS) [50,51]. The Medication Contract specified the
conditions under which opioids would or would not be
prescribed.
The clinical pharmacist or psychiatrist modified or titrated
a patient's pain medications in consultation with the pri-
mary care physician. During titration of medications,
patients returned at one month intervals. Medical man-
agement adhered to published guidelines and expert
opinion on the management of chronic, non-cancer pain
[17,52-54]. The principles of management were:
• Longer-acting opioids (long-acting morphine, fentanyl
patches, methadone, sustained-release oxycodone) were
initiated in patients who had been receiving short-acting
agents that were only partially effective.
• Short-acting, potent opioids (usually oxycodone prepa-
rations) were prescribed for breakthrough pain.
• Longer-acting opioids were titrated at interval visits.
• Less costly, generic medications (e.g. methadone and
long-acting morphine) were preferred over proprietary
products of equal or lesser efficacy [55].
• Tricyclic anti-depressants, gabapentin, and other agents
were used adjunctively, especially for neuropathic pain.
To address psychiatric comorbidity, patients with depres-
sion and other complex psychiatric conditions (e.g. psy-
chotic depression and bipolar disorder with substance
misuse) received psychiatric evaluation. Depression was
diagnosed based on clinical interview and CESD score. In
addition, primary care physicians could request psychiat-
ric consultation on patients who had unaddressed psychi-
atric problems. The clinical pharmacist, psychiatrist and
primary care physicians used CESD scores to guide treat-
ment of patients scoring in the depressed range. The pro-
gram, however, did not employ a strict protocol for
depression treatment.
As defined in our medication agreement with participants,
we prospectively monitored substance misuse through
clinical history, review of medications, communication
with pharmacies and providers, and urine toxicological
screening (UTS). Medications were documented in the
electronic medical record and our program database. Dis-
crepencies and inconsistencies were discussed with the
patient's primary provider. We contacted a patient's phar-
macy to verify procurement of medications, and, if sub-
stance misuse was suspected, we contacted additional
pharmacies to ascertain whether or not a patient was
receiving opioids from multiple sources. A UTS was
obtained at each visit and was correlated with the patient's
reported history of medication use. In collaboration with
our institution's toxicologist, results of the UTS were veri-
fied using the appropriate confirmatory assays. For exam-
ple, the presence or absence of "opiates" on the UTS was
confirmed using gas chromatography. In addition, all
positive results for amphetamines were confirmed with
gas chromatography due to the possibility of assay inter-
ference from other medications [50,51].
We defined serious substance misuse prospectively as any
of the following: 1. Cocaine or amphetamines detected on
UTS; 2. Procurement of opioids from more than one pro-
vider on a regular basis ("doctor collecting"); 3. Diversion
of opioids; 4. UTS negative on at least two occasions for
prescribed opioids in the context of a reported history that
the patient was taking the medication as prescribed (We
considered repeatedly "negative" urines as an indicator of
possible diversion.); 5. UTS positive on at least two occa-
sions for opioids not prescribed by our practice (an inap-
propriate or inconsistent urine). A positive cannabinoid
finding on UTS was not defined as serious substance mis-
use for the purposes of our study, but we counseled
patients to refrain from marijuana use.
Patients were advised at entry into our program (and in
the Medication Contract) that serious violations of the
contract would result in discontinuation of opioids. Past
instances of serious misuse were not subject to sanction.
We constituted a formal practice-wide committee to eval-
uate and respond to suspected misuse. It consisted of the
practice director, two attending physicians, a clinical phar-
macist, two resident physicians, and a nurse. The commit-
tee deliberated through secure email and considered the
violations defined above. Patients committing serious
substance misuse were offered referral to substance abuse
experts at our institution. In most cases, opioid therapy
would be reconsidered in 6 months if the patient
participated in substance abuse counseling (The practicePage 3 of 13
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dix B.).
Reassessment
At 3 month follow-up, a research assistant reassessed each
patient's clinical status. Pain, disability, and mood scores
were re-measured using the instruments previously
described. The research assistant was not blinded to study
participation status.
Analysis
Descriptive statistics are reported as means and percents.
Paired t-tests were used to compare changes in pain, disa-
bility and depression scores from baseline to 3 month fol-
low-up. McNemar's test was used to measure differences
in proportions of patients receiving treatment for depres-
sion at 0 and 3 months. We also compared changes in
pain scores based on changes in opioid dose. All analyses
were performed using Stata 7.0 (College Station, TX).
The research protocol was approved by the University of
North Carolina School of Medicine Committee on the
Protection of the Rights of Human Subjects. The funding
sources had no role in the collection or interpretation of
the results.
Results
Between December 2002 and May 2003, 85 patients
agreed to participate in the study. Table 1 presents the
baseline demographic characteristics of the study partici-
pants. All patients completed baseline assessment and 63
(73%) completed the 3 month assessment. Of the 22
patients who did not complete 3 month assessment, 15
did not return after a serious violation of the medication
contract led to the discontinuation of opioids, 4 patients
were lost to follow up, and 3 changed their venue of pri-
mary care. There were no important differences in base-
line demographic, pain, depression, or disability scores
between completers (n = 63) and all non-completers (n
== 22), although some differences emerged among non-
completers who committed substance misuse (n = 15)
(Table 2.).
Patient characteristics
The average age of patients was 51 years, 60% were male,
and 78% were white, most (83%) had an income less than
$20,000 per year and 65% were disabled. Forty-four per-
cent had a history of illicit substance use (e.g. marijuana,
cocaine, amphetamines). All patients had pain of at least
3 months duration and 90% had pain for greater than 1
year. At baseline 93% were receiving opioids. At 3 month
follow up, 97% were receiving opioids.
Table 3 presents the principal pain types. The lumbar
spine was the most frequently involved primary site.
Overall, axial spine pain accounted for 49% of the pri-
mary pain reported by patients. Myofascial pain and
polyarticular arthritis were also frequently represented.
Patients in the "Other" category commonly had mixed eti-
ologies of pain, often attributable to previous trauma or
surgery. One chronic headache patient is included in this
category.
Effect of the intervention
Table 4 presents the effect of the intervention on pain,
functional status and depression. Baseline results reveal
high pain scores. The worst pain was 9.2, the least pain
was 4.6, the average pain was 6.5, and current pain was
6.8. The average PDI score, 47.0, suggested substantial dis-
ability. There was a high prevalence of depression. The
mean CESD score, 24.0, falls in the "severely depressed"
category of the scale.
At 3 month follow up, BPI pain scores improved by 12%
to 15%, and all reductions were statistically significant.
The mean depression score improved from 24.0 to 18.0 (p
< 0.001), and the proportion of patients scoring in the
depression range decreased from 79% to 54% (p = 0.003).
We did not correct for multiple comparisons because of
the exploratory nature of our analyses.
Some authors have demonstrated that the conventional
cutoffs for the CESD (depression ≥ 15; severe depression
≥ 22) may lack specificity in patients with chronic pain
and have proposed a CESD threshold of 27 for diagnosing
Table 1: Univariate Analysis
N = 85
Mean age, y (± SD) 51 (9.6)
Range 27–76
Male, % 60
White Race, % 78
Marital Status, %
Married 49
Stable relationship 7
Unmarried 44
Disabled, % 65
Education, %
Not high school graduate 38
HS graduate 28
Some college 34
Income <$20,000/yr, % 83
Medicare or Medicaid, % 58
Uninsured,% 29
History of Smoking, % 87
H/O Alcohol Use, % 75
H/O Substance Use, % 44
H/O Depression, % 51Page 4 of 13
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the proportion of patients scoring in the depressed range
decreased from 38% to 24% (p = 0.049).
Pharmacologically, depression was undertreated at base-
line. The proportion of depressed patients receiving anti-
depressants increased from 44% at baseline to 52% at 3
months (p= 0.059).
Relationship between pain and opioid dosing
The mean daily opioid dose in milligram equivalents of
morphine increased from 72 mg per day to 91 mg per day
(A milligram morphine equivalent approximates a milli-
gram of oxycodone.). Forty-eight percent of patients had
their opioid dose increased over 3 months. In these
patients, the mean opioid equivalent increased from 53
mg to 105 mg per day. No clear relationship emerged
between opioid dosing and improvements in pain, disa-
bility, and depression scores, after adjusting for baseline
pain, disability and depression (Table 5.).
Substance misuse
Twenty-seven patients (32%) committed some form of
serious substance misuse (Table 6.). Although we con-
firmed only one instance of diversion, we suspect that
patients with repeatedly negative UTS's or inconsistent
UTS's may have been diverting their medications.
Substance misusers accounted for the preponderance of
subjects who dropped out of the study. Table 2 compares
selected baseline characteristics between substance misus-
ers who did not complete three months and subjects who
completed the trial. Although the numbers are small,
there is a trend toward greater representation of non-white
race, history of illicit substance use, worse depression, and
higher pain scores at baseline assessment among sub-
stance misusers who did not complete the trial.
Discussion
We found that a multi-disciplinary, primary care-based,
disease management program can improve pain, depres-
sion and disability scores in opioid-treated patients with
chronic pain in a 3 month uncontrolled trial. The
improvements across all outcomes support an improved
quality of life resulting from the intervention. These
improvements were obtained using an approach that bal-
anced the potential benefits and adverse effects of opioids.
Table 2: Characteristics of Study Completers and Non-Completers
Characteristic Completers (N = 
63)
Non-Completers 
(N = 22)
P-Value Non-Completers 
with Substance 
Misuse (N = 15)
P-Value
Age, y 51 49 0.422 48 0.215
% Male 62 55 0.544 67 0.732
% White 81 68 0.216 60 0.083
% High School 
Graduate
62 62 0.975 64 0.890
% Disabled 66 63 0.815 54 0.405
% Uninsured 29 32 0.774 33 0.716
% Substance Use 40 55 0.226 67 0.059
CESD 24 27 0.416 31 0.050
PDI 47 41 0.141 46 0.810
Pain Scores
Worst in last 
month
9.2 9.3 0.727 9.2 0.946
Least in last month 4.6 4.4 0.768 4.7 0.884
Average in last 
month
6.5 6.5 0.925 6.6 0.861
Current pain 6.8 7.3 0.361 7.5 0.279
Table 3: Primary Pain Type (N = 85)
Number (%)
Spine 42 (49)
Lumbar 30 (35)
Cervical 7 (8)
Thoracic 5 (6)
Diffuse (Fibromyalgia, Chronic 
fatigue syndrome)
13 (15)
Polyarthritis 8 (9)
Knee 5 (6)
Abdomen 4 (5)
Diffuse neuropathic 4 (5)
Elbow & Hip 2 (2)
Other 7 (8)Page 5 of 13
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combined effects of systematizing pain management and
treating depression. Improvements appear independent
of opioid dosing. The clinical significance of the 12% to
15% improvement in pain scores is unclear. Uncontrolled
trials in specialty pain clinics have reported a 20% to 25%
reduction in pain scores [57]. Some research suggests that
a 30% decrease in pain scores (i.e. about 2 points) repre-
sents clinically significant relief of pain [58], but the issue
of how to interpret pain scales clinically is not resolved.
The improvement in depression scores was clinically
important and may reflect combined effects of intensifica-
tion of pharmacological management for depression and
pain and the systematization of care. Although the recip-
Table 4: Pre and Post Intervention (N = 63)
Pre Post Improvement, % P-Value*
Pain at worst in the last 
month&
9.2 8.1 12 <0.001
Pain at least during the last 
month
4.6 3.9 15 0.038
Pain on average during the 
last month
6.5 5.5 15 0.003
Pain right now 6.8 5.8 15 0.014
Pain Disability Index 47.0 39.3 16 <0.001
CESD 24.0 18.0 25 <0.001
% CESD in depression range:
Conventional cutoffs£ 79.4 54.0 32 0.003
Chronic pain cuttoffs¶ 38.1 23.8 37 0.049
% Depression medication 44.4 52.4 15 0.059
* Paired t-test except where indicated 
McNemar's test
&Score 1–3 is mild pain; 4–6, moderate pain; 7–10, severe pain
£ Score of ≥ 15
¶Score of ≥ 27
Table 5: Effect of Opioid Increase on Pain (N = 63)
Opioids Increased P-Value
Yes (n = 30) No (n = 33)
∆ Pain at worst in the last month 1.40 0.99 0.37*
∆ Pain at least during the last month 0.80 0.52 0.66*
∆ Pain on average during the last month 0.96 0.94 0.93*
∆ Pain right now 1.14 0.87 0.70*
∆ Pain Disability Index 8.34 7.03 0.63¶
∆ CESD 5.21 6.71 0.74
* Adjusted for baseline pain
¶Adjusted for baseline PDI
 Adjusted for baseline CESD
Table 6: Substance Misuse (N = 27)
Misuse Number (%)
Stimulants on UTS 13 (15)
Cocaine 11 (14)
Amphetamines 2 (2)
Diversion 1 (1)
Doctor collecting 3(3)
Inappropriate/Inconsistent UTS 2 (2)
Negative ("Clean") Urines 7 (8)
Prescription adulteration 1 (1)Page 6 of 13
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established in previous studies, the effect that treating one
condition has on the other has not been well-assessed
[29]. One recent study demonstrated that the presence of
severe pain predicted a poor response to antidepressant
therapy, and thus it is plausible that intensifying pain
management would have a beneficial effect on depression
[59]. Clearly, the improvements in depression scores seen
in this study cannot be attributed to increasing anti-
depression pharmacological therapy alone because the
proportion of patients treated with anti-depressants
increased from 44% to 52% only. We have since added a
structured treatment algorithm to increase the use of anti-
depressants. It is important to note that there was a statis-
tically signficant trend toward greater depression among
substance misusers who did not complete the trial; thus,
it is possible that the trial overestimates the effect of multi-
disciplinary management on depression outcomes.
To our knowledge, this is the first study to prospectively
examine the effects of multi-discplinary pain manage-
ment on the outcomes of pain, disability, depression, and
substance misuse in an academic primary care practice
caring for a wide range of patients. Previous studies con-
ducted in a military clinic[60] and a health maintenance
organization [26] demonstrated improved pain and func-
tional scores with systematic, multidisciplinary interven-
tion. The military trial was uncontrolled and enrolled
referred patients into a specialty clinic. The HMO trial was
conducted in a primary care setting. It was controlled, and
did evaluate pain, function and mood outcomes. Neither
study systematically monitored substance misuse.
We documented a high prevalence of substance misuse
(32%). We did not assess addiction per se. The prevalence
of substance misuse and addiction in patients receiving
chronic opioids is unclear and depends on the populaton
under study. Some authors have asserted that addiction
and substance misuse are uncommon consequences of
opioid use for pain. One widely cited reference estimated
the prevalence of addiction at approximately 4 in 10,000
treated patients [61]. Others have reported prevalences of
addiction ranging from 3% to 17% [62,63]. A recent ret-
rospective study in a primary care setting documented a
high prevalence of opioid misuse: 24% in a resident
physician clinic and 31% in a Veterans Administration
outpatient clinic[64], but the criteria used to determine
the prevalence of opioid misuse were limited by chart
review. Some behaviors defined as indicators of opioid
misuse (e.g. lost or stolen medications, requests for early
refills) could be construed as indicators of inadequately
treated pain (i.e. "pseudoaddiction"[65]) and not sub-
stance misuse or addiction.
Opioid misuse not only complicates the management of
pain in the individual patient, but has negative societal
consequences as well, especially when opioids are
diverted from their intended use [66-68]. Several states
have documented increases in unintentional deaths from
opioids, especially diverted methadone [69-71]. National
surveys demonstrate dramatic increases in the non-medi-
cal use of OxyContin® and other prescription drugs among
teens and young adults [72,73]. The trauma literature has
documented recent increases in opioid use among
patients admitted to trauma centers [74]. In response,
there have been state and national initiatives to reduce
prescription drug misuse [75,76]. Though high rates of
substance misuse are a source of concern, our program
may serve as an example for how care can be organized to
reduce misuse without eschewing the benefits of opioid
medications.
Although the prevalence of substance misuse in our study
population is higher than reported in clinical trials of opi-
oids, these trials have occurred in specialty settings with
selected populations. They excluded patients with a his-
tory of substance misuse, or have not systematically mon-
itored patients for substance misuse [11,12,23,66,77]. In
addition, they commonly excluded patients with psychi-
atric illness (including depression) which is a strong pre-
dictor of substance misuse [23,66,78-80]. Patients in our
program had a high baseline prevalence of depression,
previous substance and alcohol abuse, and other psychi-
atric disorders (Table 1.). The strong relationship between
mental illness and substance abuse disorders is well
known and thus the high prevalence of substance misuse
is not entirely unexpected [81]. Previous studies of mental
illness have documented a high coexisting prevalence of
substance and alcohol misuse: 32% with unipolar depres-
sion; 61% with bipolar depression; 47% with schizophre-
nia; 84% with personality disorders: and 24% with
anxiety disorders [78,82].
We specifically sought out patients whose pain manage-
ment was difficult for providers or in whom substance
misuse was suspected. Many had established or suspected
psychiatric diagnoses. How to identify chronic pain
patients at risk for drug misuse and to treat their pain
remains a challenge [83-89]. The pattern of substance
misuse in our population often suggested polysubstance
abuse; this places patients at especially high risk of mor-
bidity and mortality [90]. Although patients committing
substance misuse were offered substance abuse treatment
referral, only two followed through and most did not
return to our program. The option of pain management
without the use of opioid analgesics was offered to all
patients who committed substance misuse.Page 7 of 13
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abuse treatment services is a pressing public health issue
and a topic of national debate in the United States [81]. In
our sample there was a clear trend toward increased
comorbid depression among substance misusers who did
not complete three month follow up (Table 2.). Despite
the availability of on-site psychiatric consultation, our
program was not successful in retaining and managing a
challenging subset of patients with substance misuse and
depression.
We are aware that some of our substance misusing
patients migrated to other practices in order to obtain opi-
oids and other controlled substances. Our program imple-
mented policies to prevent migration of patients within
our practice (Appendix B.) and the University of North
Carolina Health Care System. The cornerstone of these
policies was meticulous documentation in an electronic
medical record that is accessible to all physicians at our
medical center and to hospitals and physicians affiliated
with our system in the surrounding communities. In gen-
eral, though, we have no direct control over migration
that occurs outside of our practice and our health care sys-
tem. In order to curtail migration and "doctor shopping,"
some states have implemented centralized monitoring
systems for opioids and other controlled substances.
North Carolina is currently exploring the feasibility of
such a system. A description of the operational state mon-
itoring programs is available online through the United
States Drug Enforcement Agency Diversion Control Pro-
gram website [91].
We believe that our results may be generalizable to other
academic primary care practices that serve diverse patient
populations with a high burden of medical and psychiat-
ric comorbidity. The etiologies and sites of pain were sim-
ilar to those reported in population-based
epidemiological surveys and clinical trials in primary care,
except that headache was under-represented in our popu-
lation [1,12,92]. The results replicate epidemiological
research that demonstrates a strong interaction between
pain and the psychiatric comorbidities of depression and
substance misuse [87,88].
Our study may be more applicable to the general medical
setting than previous trials examining the effects of opio-
ids on chronic pain because we did not exclude patients
with serious psychiatric comorbidity or those suspected of
substance abuse. To be effective, pain management
should encompass more than pharmacological manage-
ment directed at pain scores; it should address a variety of
behavioral and psychosocial factors that contribute to suf-
fering [86,93].
Our study has several limitations. It was uncontrolled and
of relatively short duration. The research assistants were
not blinded to pre- and post-treatment assessments. The
improvements could reflect secular trends, although the
chronic nature of our patients' symptoms and disability
makes this less likely, and improvements were noted
across all of the pre-specified outcomes. Not all patients
receiving chronic opioids in our practice were referred.
Thus, we may have over-estimated the prevalence of
substance misuse because providers were more likely to
refer "problem" patients in whom they suspected opioid
misuse.
Another limitation of our study is its individualized
nature. We did not adhere to strict algorithms for
diagnosis and treatment and did not test a single interven-
tion. The evidence-base for managing chronic pain in the
general medicine setting is limited and the multi-modal
nature of our intervention was by necessity empirical and
exploratory. As such, we decided to allow more latitude
and individualization in treatment choice. We have used
our experience and the data collected to develop more
robust algorithms to guide the management of pain and
depression and to make psychiatric referral when
appropriate.
As a corollary to our multi-modal approach, it is difficult
to ascertain if the improvements derived from pain medi-
cations, intensification of depression therapy, or simply
participation in an organized program. Improvements
and changes in behavior that occur as a result of becoming
a target of special interest in a program are often referred
to as a Hawthorne effect [94,95].
Conclusions
In a 3 month trial conducted in an academic primary care
setting, a systematic, multi-disciplinary approach to
chronic pain management that included the use of opio-
ids and tools to prevent misuse was effective in improving
pain, depression, and function scores. Future efforts will
be directed at examining their durability and promoting
their sustainability. A randomized control trial would
determine whether these are real effects or represent a sec-
ular trend.
Comorbid depression and substance misuse were com-
mon. Efforts will also be made to further characterize the
interaction of these and other comorbid psychiatric con-
ditions with chronic pain. Chronic pain patients with sub-
stance abuse are a challenging subset of patients who
could benefit from new research and initiatives to miti-
gate the risk of abuse while ameliorating pain control.Page 8 of 13
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Appendix A: Medication Contract
Patient Name ____________________________ Diagnosis
______________________________
Physician Name __________________________ Tele-
phone Number _______________________
I agree to abide by the following guidelines for managing
my prescription for opiate pain medications:
1. I will only request and receive opiate (narcotic) pain
medications from Dr. _________ or from his/her designee
in the Internal Medicine Clinic Pain Service. I agree to
inform any other physicians participating in my care of
this agreement. If another physician wishes to suggest
changes in pain management, they can contact Dr.
___________ during regular business hours, but no
changes will be made without such contact.
2. Dr. ____________ and I have agreed that I will receive
the following:
medicine ______________, directions __________ quan-
tity _____, per ___ days,
medicine ______________, directions __________ quan-
tity _____, per ___ days,
medicine ______________, directions __________ quan-
tity _____, per ___ days.
I will not request refills prior to this date. I understand
that if my medicines are lost or stolen, they will not be
refilled prior to the next refill date. If I use up my supply
of medication before the date of the next refill, I
understand that my doctor will not provide extra medica-
tion. I further understand that I may suffer symptoms of
withdrawal. I will inform my doctor in a timely manner if
I miss taking a dose of my medication, have an increased
need for the pain medication, or have difficulty taking the
medication as prescribed. If I find that the current dose of
pain medication is no longer adequate, I will discuss this
situation with my doctor at a scheduled visit.
3. I agree to use
_________________________________________________
Pharmacy, located at
_________________________________________________
____________, telephone ________________________, for
filling prescriptions for all of my pain medicine.
4. I will bring all unused pain medicine to every office
visit, including all current prescription vials.
5. While this contract is in effect I will not abuse alcohol
or other illicit drugs. As a part of this program, urine drug
screening will occur at enrollment and may be required at
future visits.
6. I will not sell or share opiate medications.
7. If I violate the terms of this contract, I understand that
my doctor and other doctors in the Internal Medicine
Clinic will no longer prescribe opiate medications for me.
If this occurs, I understand that I may receive care else-
where or continue with my current doctor and not receive
opiate medicines. If I change doctors, I agree to allow my
current physician to contact my new physician to transfer
medical information including information about
chronic pain treatment.
8. I understand that my doctor may verify whether or not
I have a history of criminal drug convictions.
Patient Signature
________________________________________________
(print name)
________________________________________________Page 9 of 13
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________________________________________________
Date
________________________________________________
Appendix B
UNC General Internal Medicine Practice
Pain Review Committee:
Policy on Serious Opioid or Controlled Substance Mis-
use & Misconduct
Definition
The Pain Review Committee defines serious misuse or
misconduct with regard to opioid medications and other
controlled substances as any of the following:
1. Forgery or alteration of prescriptions.
2. Use of cocaine or other stimulant medications (e.g.
amphetamines) concurrently with prescribed opioids and
their detection on urine toxicological testing. Stimulant
abuse is strongly indicative of polysubstance abuse.
3. Diversion of opioids or controlled substances.
4. Doctor collecting or shopping: Procuring controlled
substances from more than one provider and misrepre-
senting the fact. This is a felony in North Carolina.
5. Negative or "clean" urines: The absence of prescribed
opioids from urine toxicological testing on at least two
occasions in the context of a history that the patient is tak-
ing the medication as directed. This finding suggests diver-
sion and/or substituting a separate urine sample.
6. Inappropriate or inconsistent urines: The presence on
urine toxicological testing of opioids or other controlled
substances (excluding cannabinoids) not prescribed by
our clinic or pain program on at least two occasions with-
out a reasonable explanation. This finding suggests
polysubstance abuse, doctor collecting, or drug bartering
(a form of diversion).
Procedure
Serious misuse or misconduct is a special category of mis-
use. It results in the immediate discontinuation of opioids
in the Internal Medicine Clinic. The Pain Review
Committee will address instances of serious misuse on an
expedited basis. Individual cases will not require the
review of the entire committee. The following procedure
applies:
• The specific violation will be documented in the elec-
tronic medical record.
• Instances of serious misuse discovered by the pain man-
agement team will be discussed with the patient's primary
care provider (PCP).
• The provider who discovers the violation will report it to
the Clinic Director, Dr. Thomas Miller, or designee on the
Pain Review Committee. (The designee will be either Dr.
Paul Chelminski or Dr. Timothy Ives.) The designee will
inform Dr. Miller of the violation and make a recommen-
dation to Dr. Thomas Miller and the entire Pain Review
Committee for the immediate discontinuation of opioids.
• Dr. Miller will make the final disposition on the
recommendation.
• Committee members will receive communication about
recommendations and disposition through email. Com-
mittee members may recommend alternative sanctions.
• The PCP will be informed of the disposition.
• The patient will receive verbal and written notice of
disposition.
Sanctions
A. Serious misuse or misconduct will lead to one of two
possible sanctions:
1. Forgery or alteration of prescriptions and diversion will
result in immediate and permanent discontinuation of
opioids and/or other controlled substances. The clinic
director will decide whether instances of forgery or diver-
sion also merit dismissal from the clinic.
2. Stimulant use, doctor collecting/shopping, negative
urines, or inappropriate urines will result in immediate
discontinuation of opioids and/or other controlled sub-
stances with possible re-evaluation in six months for a
first violation. The Committee will stipulate substance
abuse counseling as a condition for re-evaluation.
B. Two serious violations of the medication contract will
result in permanent discontinuation of controlled
substances.
Provider IssuesPage 10 of 13
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physicians to cease prescribing opioids or other controlled
substances; however, providers who continue to prescribe
these medications must understand that this practice may
jeopardize their DEA license and/or expose them to regu-
latory and even criminal investigation. If the attending
continues to prescribe opioids after a recommendation of
discontinuation by the Committee, the patient is not eli-
gible for re-enrolment in the General Internal Medicine
Pain Program after six months.
2. The responsibility for stewardship and teaching of resi-
dent physicians requires special oversight of residents'
patients who receive controlled substances. The residency
program has an obligation to promote appropriate clini-
cal practice and protect residents from practices that may
jeopardize their professional status. In addition, residents
prescribe scheduled substances under the authority of the
hospital's DEA number, and the inappropriate prescrip-
tion of opioids may expose the hospital to sanction. If the
committee recommends discontinuation of opioids for
the patient of a resident, the committee will instruct the
resident that he or she can no longer prescribe scheduled
medications for this patient. Likewise, other residents in
the practice are not authorized to prescribe opioids to
patients of residents or attendings who have had opioids
discontinued.
Communication of Decisions
1. The patient should be informed of discontinuation ver-
bally. Usually, this responsibility will fall to the PCP, but
in certain instances it may fall to the person discovering
the violation (e.g. the pharmacist who sees the patient in
clinic for follow up in the pain program).
2. Dr. Miller will send the patient a registered letter.
3. The PCP will be copied on the letter.
4. A copy of the letter will be entered into the permanent
electronic medical record as a Phone Message.
5. The patient's problem list on the electronic medical
record will contain the entry "VIOLATION OF MEDICA-
TION CONTRACT" and will be annotated "PATIENT VIO-
LATED THE MEDICATION CONTRACT SIGNED WITH
GENERAL MEDICINE, AND WAS DISMISSED FROM
NARCOTICS – SEE [date] CIS NOTE."
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